This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parmley, W. W. Search for Related Content PubMed PubMed Citation Articles by Parmley, W. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DIGOXIN SPIRONOLACTONE Medline Plus Health Information Heart Failure Related Collections Congestive Remodeling Growth factors/cytokines

(Circulation. 2001;103:1611.)
© 2001 American Heart Association, Inc.

Editorial

How Many Medicines Do Patients With Heart Failure Need?

William W. Parmley, MD

From the University of California at San Francisco.

Correspondence to William W. Parmley, MD, Professor of Medicine, UCSF, 1180 Moffitt Hospital, 505 Parnassus Ave, San Francisco, CA 94143-0124. E-mail parmley@medicine.UCSF.edu

Key Words: Editorials • heart failure • remodeling

Over the past 2 decades, a number of controlled clinical trials have been performed that have taught us that polypharmacy for heart failure is necessary to achieve the best reduction in morbidity and mortality. Four drugs are given to patients with moderately severe heart failure: digoxin, a loop diuretic, an ACE inhibitor, and a ß-blocker. Although no mortality trials have been done with diuretics, the clinical experience is that they are both necessary and effective agents for reducing volume overload and decreasing symptoms of dyspnea. Although the Digitalis Investigation Group did not show any reduction in mortality with digoxin, there was a reduction in the hospitalization rate.¹ Furthermore, other trials have shown clinical benefit with this drug. Both ACE inhibitors and ß-blockers have a plethora of evidence showing that they reduce mortality and morbidity in patients with heart failure.^{2 3 4 5} In class IV patients, the aldosterone antagonist spironolactone also reduced mortality.⁶ Whether spironolactone is also beneficial in less severe heart failure is not known, but it is increasingly being used in that setting. Some data indicate that ß-blockers may be helpful in patients with class IV heart failure (Carvedilol Prospective Randomized Cumulative Survival [COPERNICUS] Trial; presented at 22nd Congress of European Society of Cardiology, August 2000). Thus, there are now 5 agents that can be considered part of standard therapy for heart failure. Despite this effective pharmacotherapy, however, patients continue to slide downhill over time and, although physicians reduce mortality with these drugs, the curve is merely shifting to the right.

. . . [Full Text of this Article]

This article has been cited by other articles:

				H. Skali, M. A. Pfeffer, J. Lubsen, and S. D. Solomon Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials Circulation, November 21, 2006; 114(21): 2298 - 2303. [Abstract] [Full Text] [PDF]

				D. J. van Veldhuisen and W. H. van Gilst The pharmacological management of heart failure: too many treatments? Eur J Heart Fail, January 1, 2003; 5(1): 5 - 8. [Full Text] [PDF]

				T. O. Cheng RENAISSANCE, RECOVER, and RENEWAL: The 3 Rs Circulation, November 13, 2001; 104 (20): e108 - e108. [Full Text] [PDF]

				W. J. Kostuk Congestive heart failure: What can we offer our patients? Can. Med. Assoc. J., October 1, 2001; 165(8): 1053 - 1055. [Full Text] [PDF]